AGL 38.50 Decreased By ▼ -0.06 (-0.16%)
AIRLINK 211.50 Increased By ▲ 3.73 (1.8%)
BOP 9.88 Decreased By ▼ -0.18 (-1.79%)
CNERGY 6.67 Decreased By ▼ -0.41 (-5.79%)
DCL 9.59 Decreased By ▼ -0.40 (-4%)
DFML 40.43 Decreased By ▼ -0.71 (-1.73%)
DGKC 100.00 Decreased By ▼ -3.46 (-3.34%)
FCCL 35.20 Decreased By ▼ -1.15 (-3.16%)
FFBL 87.50 Decreased By ▼ -4.09 (-4.47%)
FFL 13.98 Decreased By ▼ -0.62 (-4.25%)
HUBC 133.49 Decreased By ▼ -5.94 (-4.26%)
HUMNL 14.00 Decreased By ▼ -0.10 (-0.71%)
KEL 5.67 Decreased By ▼ -0.30 (-5.03%)
KOSM 7.25 Decreased By ▼ -0.61 (-7.76%)
MLCF 46.00 Decreased By ▼ -1.28 (-2.71%)
NBP 66.38 Decreased By ▼ -7.38 (-10.01%)
OGDC 218.50 Decreased By ▼ -4.16 (-1.87%)
PAEL 39.00 Increased By ▲ 0.89 (2.34%)
PIBTL 8.96 Decreased By ▼ -0.31 (-3.34%)
PPL 198.20 Decreased By ▼ -7.65 (-3.72%)
PRL 40.40 Increased By ▲ 0.55 (1.38%)
PTC 25.80 Decreased By ▼ -0.82 (-3.08%)
SEARL 102.85 Decreased By ▼ -7.39 (-6.7%)
TELE 9.05 Decreased By ▼ -0.18 (-1.95%)
TOMCL 36.90 Decreased By ▼ -1.31 (-3.43%)
TPLP 14.05 Increased By ▲ 0.28 (2.03%)
TREET 25.40 Decreased By ▼ -1.05 (-3.97%)
TRG 58.40 Decreased By ▼ -2.14 (-3.53%)
UNITY 33.80 Decreased By ▼ -0.34 (-1%)
WTL 1.71 Decreased By ▼ -0.17 (-9.04%)
BR100 11,957 Decreased By -341.5 (-2.78%)
BR30 37,521 Decreased By -1356 (-3.49%)
KSE100 111,611 Decreased By -3249.6 (-2.83%)
KSE30 35,071 Decreased By -1124.8 (-3.11%)

ROME: A top official in the European Medicines Agency said it might be worth abandoning AstraZeneca’s coronavirus vaccine for all age groups where alternatives are available, in an interview published Sunday.

Marco Cavaleri, the EMA’s head of vaccine strategy, also told Italy’s La Stampa newspaper that the Johnson & Johnson jab should be preferentially used for the over 60s.

Both so-called viral vector vaccines are authorised for everyone over 18 but have been dogged by reports of rare blood clots. The EU has also authorised two mRNA vaccines, Pfizer/BioNTech and Moderna.

Italy on Saturday restricted AstraZeneca vaccines to people aged 60 and over following concerns about the heightened health risks for younger people.

Asked if it would not be better to ban AstraZeneca including for the over 60s, Cavaleri said: “Yes, and it is an option that many countries, such as France and Germany, are considering in the light of the increased availability of mRNA vaccines.

“However, incidents were very rare and after the first dose. It is true that there is less data on the second dose, but in the United Kingdom it (the vaccination programme) is going well.”

He added: “Among young people the risks of illness decrease, and the message for them could be to use preferentially the mRNA vaccines, but the choice is left to individual states.”

Comments

Comments are closed.